Concepedia
Statistics
Publications
4
Citations
77
H-Index
Active since
2014
Affiliations
Novo Nordisk (Denmark)(Current)
Jaslok Hospital
Universiti Sains Malaysia
E. Hammerby is an author at Novo Nordisk (Denmark).
Publications per year
2014–2021
An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes
Vishal Gupta, Ranya Baabbad, E. Hammerby et al. · Journal of Medical Economics · 2014 · 24 citations
An analysis of the short- and long-term cost-effectiveness of starting biphasic insulin aspart 30 in insulin-naïve people with poorly controlled type 2 diabetes
Asrul Akmal Shafie, Vishal Gupta, Ranya Baabbad et al. · Diabetes Research and Clinical Practice · 2014 · 20 citations · Full text
The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data
Andrew Briggs, Shuaib Nasser, E. Hammerby et al. · Journal of Patient-Reported Outcomes · 2021 · 19 citations · Full text
Improvements in quality of life associated with biphasic insulin aspart 30 in type 2 diabetes patients in China: results from the A1chieve® observational study
Wenying Yang, Xiaoming Zhuang, Yukun Li et al. · Health and Quality of Life Outcomes · 2014 · 14 citations · Full text
1–4 of 4